DERM is selling off to Lilly for $1.1B after a phase 2B study. Who would want herpes just to get rid of atopic dermatitis. Not me.
The most common adverse events reported across the lebrikizumab 250mg Q2W, 250mg Q4W and 125mg Q4W dosing arms were upper respiratory tract infection (2.7%, 11.3% and 8.2%, respectively, vs. 5.8% for placebo), nasopharyngitis (12.0%, 2.5% and 5.5%, respectively, vs. 3.8% for placebo), headache (5.3%, 1.3% and 4.1%, respectively, vs. 5.8% for placebo) and injection site pain (5.3%, 3.8% and 0.0%, respectively, vs. 1.9% for placebo). Rates of herpes viral infections (which includes oral herpes, herpes zoster, genital herpes, herpes simplex, and eczema herpeticum) were 2.7%, 5.0% and 2.7%, respectively, vs. 3.8% for placebo) and conjunctivitis (2.7%, 3.8% and 1.4%, respectively, vs. 0.0% for placebo) were low. Across all studies of lebrikizumab conducted to date in atopic dermatitis, conjunctivitis has been reported at low rates similar to those in patients receiving placebo.